Background

Dr. Eric M. Hecht, M.D serves as the President and Secretary of 8 By 8, Inc. Dr. Hecht serves as Chief Executive Officer of Gabriel Pharma. He was Research Analyst of BofA Merrill Lynch, Research Division. He served as the President, Chief Financial Officer and Principal accounting officer of Alsius Corp. (formerly known as Ithaka Acquisition Corp.) since April 4, 2005. Since January 2003, Dr. Hecht served as the Chief Executive Officer of Potomac Pharma Inc., a private ... specialty pharmaceutical company. He founded Conceptis Technologies Inc., a privately held healthcare information company that operates the premier cardiology. From January 1997 to December 2002, he served as a Senior Biotechnology Analyst for Merrill Lynch and from September 1992 to December 1996, he served as a Senior Research Analyst for Morgan Stanley, Research Division. While at Merrill Lynch and Morgan Stanley, Dr. Hecht focused on biotechnology companies. Dr. Hecht established his well known reputation during his 10 year tenure as one of the top biotechnology analysts on Wall Street. During the period from 1992 to 2002, he was selected to the Institutional All-Star Team a total of six times making him one of the foremost experts in the industry. He serves as an Executive Chairman of Houston Pharma, a private biotech company. He has been a Director of Alsius Corporation since June 2007. Dr. Hecht has been a Director of ALUS Liquidation Corp. since June 2007. He serves as Director of 8 By 8, Inc. He served as a Director of GMP Companies Inc., a holding company of LifeSync Corporation. He served as External Director of Conceptis Technologies Inc. He served as a Director of Ithaka Acquisition Corp., since April 4, 2005. He served as a Director of Cambridge Heart Inc. from December 8, 2003 to October 19, 2004. Dr. Hecht received a B.S. from Touro College in 1984 and an M.D. from the Albert Einstein College of Medicine in New York in 1990.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.